Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TADPOLE: Dabrafenib + Trametinib in Pediatric Glioma
NCT02684058Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2017
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 2, randomised, open-label trial of dabrafenib + trametinib and trametinib in glioma (3 arms), sponsored by Novartis. Primary endpoint: Overall Response Rate at 3.2 years. Started Dec 2017; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02684058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02684058.